Lab
Secon of New England LLC
Secon of New England LLC was paid $8.88M by Medicaid between Jan 2018 and Oct 2024, across 15 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 43% of everything it billed.
33Billing provider infoSECON OF NEW ENGLAND LLC
WORCESTER, MA 01608
WORCESTER, MA 01608
33aNPI1487659694assigned 06/15/2005
33bProvider typeClinical Medical Laboratory
28Total paid$8.88M
24GClaims223,611
24DCodes billed15
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#8 of 63
Median peer was paid$473K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 89,239 | $3.63M | |
| 2019 | 105,609 | $4.05M | |
| 2020 | 26,911 | $1.16M | |
| 2021 | 148 | $7K | |
| 2022 | 742 | $11K | |
| 2023 | 712 | $14K | |
| 2024incomplete | 250 | $10K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 43% | 110,963 | 51,797 | $3.82M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 38% | 85,162 | 40,587 | $3.36M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 18% | 25,151 | 14,985 | $1.58M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.1% | 1,274 | 895 | $94K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 100 | 89 | $14K |
| 81025 | <1% | 775 | 326 | $4K | |
| 82570 | <1% | 55 | 51 | $32.39 | |
| 80365 | 0% | 13 | 12 | $0.00 | |
| 80325 | 0% | 13 | 12 | $0.00 | |
| 80346 | 0% | 16 | 15 | $0.00 | |
| 80354 | 0% | 13 | 12 | $0.00 | |
| 83986 | 0% | 26 | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFREEMAN, SYLVIA (MGR OF CREDENTIALING/ENROLLMENT)
| Provider | Location | Paid |
|---|---|---|
| Regional Toxicology Services, LLC | Tacoma, WA | $60.35M |
| American Forensic Toxicology Services LLC | Huntington, NY | $33.21M |
| Rocky Mountain Tox, LLC | Aurora, CO | $236K |
| Technical Resource Management LLC | Indianapolis, IN | $119.72 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.